{"filing":{"accession_number":"0001213900-26-090482","cik":"0001513525","ticker":"ADIL","company_name":"ADIAL PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-08-17","report_date":"2026-08-17","primary_document":"ea0301966-8k_adial.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390026090482/ea0301966-8k_adial.htm"},"events":[{"id":28077,"run_id":25661,"accession_number":"0001213900-26-090482","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The filing discloses quarterly financial results for Q2 2026 (ended June 30, 2026) via a press release attached as Exhibit 99.1. The Item 2.02 section explicitly states the Company \"issued a press release that included financial information for its quarter ended June 30, 2026,\" and the press release reports key metrics including cash position ($28.7M), R\u0026D expenses ($440K), G\u0026A expenses ($5.4M), net loss ($52.0M), and loss per share ($(11.25)). While the filing also discloses concurrent M\u0026A activity (Azora acquisition) and financing, the Item 2.02 classification and the press release structure center on the quarterly earnings disclosure.","company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","filing_date":"2026-08-17","form":"8-K","submitted_at":null,"items":[{"id":29877,"accession_number":"0001213900-26-090482","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses quarterly financial results for Q2 2026 (ended June 30, 2026) via a press release attached as Exhibit 99.1. The Item 2.02 section explicitly states the Company \"issued a press release that included financial information for its quarter ended June 30, 2026,\" and the press release reports key metrics including cash position ($28.7M), R\u0026D expenses ($440K), G\u0026A expenses ($5.4M), net loss ($52.0M), and loss per share ($(11.25)). While the filing also discloses concurrent M\u0026A activity (Azora acquisition) and financing, the Item 2.02 classification and the press release structure center on the quarterly earnings disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T11:56:19.235725+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29877,"accession_number":"0001213900-26-090482","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses quarterly financial results for Q2 2026 (ended June 30, 2026) via a press release attached as Exhibit 99.1. The Item 2.02 section explicitly states the Company \"issued a press release that included financial information for its quarter ended June 30, 2026,\" and the press release reports key metrics including cash position ($28.7M), R\u0026D expenses ($440K), G\u0026A expenses ($5.4M), net loss ($52.0M), and loss per share ($(11.25)). While the filing also discloses concurrent M\u0026A activity (Azora acquisition) and financing, the Item 2.02 classification and the press release structure center on the quarterly earnings disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T11:56:19.235725+00:00","company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","filing_date":"2026-08-17"}]}